Coronaviruses are a large family of viruses that are common in people and animals. SARS-CoV-2, a novel coronavirus, causes a respiratory disease called coronavirus disease 2019, abbreviated COVID-19.1,2 Immunocompromised patients, especially those who have cancer and undergoing treatment, pose to ...
According to the American Cancer Society, between 80 and 100% of patients with cancer report fatigue.1 Fatigue can be present while receiving active anticancer treatment and can persist for as long as 12 months after treatment cessation. In 2000, the National Comprehensive Cancer Network (NCCN) ...
Although treatment strategies for patients with metastatic gastric cancer who have failed prior lines of therapy remain limited, novel agents such as trastuzumab deruxtecan (Enhertu), provide further options for patients with HER2-positive disease.
Immunoglobulin light-chain (AL) amyloidosis is a malignancy of the plasma cells which express CD38 and produce misfolded proteins that lead to organ damage, primarily of the heart and kidneys. The standard treatment of AL amyloidosis is bortezomib, cyclophosphamide, and dexamethasone which is ...
On August 13, 2021, the Food and Drug Administration (FDA) expanded the Emergency Use Authorization for the Pfizer and Moderna COVID-19 vaccines to recommend a third dose for certain immunocompromised patients.1 This recommendation was based on data suggesting that these patients experienced ...
Beth Sandy, MSN, CRNP
Read more
Avani Yenamandra, PharmD
.png?width=40&name=Untitled%20design%20(2).png){kind=avatar}
Christian Watts Pharm.D., MSHI Candidate, Larry Buie Pharm.D., BCOP, FCCP, FASHP, Beth Sandy, MSN, CRNP
Amari Marshall & Abigail Shockley, PharmD
Christina Bartholomew
Marissa Duco, PharmD
Alice Wang, PharmD